An interventional study of Clopidogrel monotherapy and Tailored anti-platelet therapy in Coronary Artery Disease, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-30.
Sponsored by Yonsei University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Coronary Artery Disease by Yonsei University — 13 open to participants now, 18 under way, none of them phase 3. Coronary Artery Disease · Yonsei University.
Among the 64 studies in Coronary Artery Disease by Yonsei University, this one is the 5th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2023, is one of 21 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 57th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →13 of the 64 studies in Coronary Artery Disease by Yonsei University are open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,434 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 540 across the 38 interventional studies, 300 across the 26 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yonsei University is the lead sponsor of 1,421 studies on the registry; 241 are open to participants now.
4 of the studies in Coronary Artery Disease by Yonsei University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05340361Yonsei UniversityEfficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT | 2026-12-31 |
| NCT05936606Yonsei UniversityTailored Anti-platelet Therapy After DES Implantation in High-risk Patients | 2027-05 |
| NCT07235657Yonsei UniversityAI-Assisted Interpretation of Cardiac CT in the Emergency Department | 2027-06 |
| NCT05488665Yonsei UniversityThe COMPLETE Treatment of Bifurcation With Two-stent Techniques: Randomized Comparison of Crush Versus Culotte Technique | 2027-09-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies in Coronary Artery Disease by Yonsei University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clopidogrel monotherapy has been found effective in reducing ischaemic cardiovascular and haemorrhagic complications in patients with drug-eluting stent (DES) placement. However, concerns remain about the safety of long-term clopidogrel monotherapy in high-risk patients with HPR (high platelet reactivity) who do not respond adequately to clopidogrel. This study aims to evaluate the effectiveness of a patient-tailored antiplatelet therapy strategy that considers platelet aggregation in high-risk patients with DES placement beyond 12 months after stenting.
This study will randomly assign eligible participants who underwent drug-eluting stent placement and have maintained the standard antiplatelet therapy for 12 months to either a control group or an intervention group. The control group will continue receiving clopidogrel monotherapy for 24 months regardless of their PRU (platelet reactivity unit) values. The intervention group will receive personalized antiplatelet therapy based on their PRU values: for non-HPR patients (PRU\<208), clopidogrel monotherapy will be continued; for HPR patients (PRU≥208), dual antiplatelet therapy will be prescribed based on clinical diagnosis at the time of stent implantation and individual patients' ischemic/bleeding risk profiles. Patients (≥50 years) who presented with acute myocardial infarction at the time of coronary intervention, and have high-risk characteristics (① ≥65 years ② multi-vessel disease ③ diabetes mellitus ④ chronic kidney disease ⑤ recurrent myocardial infarction) will receive ticagrelor 60 mg twice daily with aspirin, whereas the remainder will receive clopidogrel with aspirin. For high-bleeding-risk patients with two or more major bleeding risk factors according to ARC-HBR, the investigator may consider early discontinuation of dual antiplatelet therapy or de-escalation therapy like aspirin monotherapy based on the patient's risk profile. The treatment assignment ratio is 1:1. The study period will be up to 24 months from the time of randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
High risk patients
High risk lesions
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will continue clopidogrel monotherapy for 24 months from randomization, irrespective of their PRU measurement.
Drug: Clopidogrel monotherapy
Patients in the intervention arm will receive tailored anti-platelet therapy according to PRU and bleeding risk
Drug: Tailored anti-platelet therapy
Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
Net Clinical Adverse Clinical Events (NACE) for 24 months
A composite of all-cause of death, myocardial infarction (MI), stent thrombosis, stroke, or BARC type 2, 3, or 5 bleeding
Time frame: upto 2 years after randomization
All-cause death
Time frame: upto 2 years after randomization
Cardiovascular death
Time frame: upto 2 years after randomization
Myocardial infarction
Time frame: upto 2 years after randomization
Stent thrombosis
Time frame: upto 2 years after randomization
Ischemia-driven target vessel revascularization
Time frame: upto 2 years after randomization
Any revascularization
Time frame: upto 2 years after randomization
Stroke
Time frame: upto 2 years after randomization
Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding
Time frame: upto 2 years after randomization
Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding
Time frame: upto 2 years after randomization
Bleeding Academic Research Consortium (BARC) type 2 bleeding
Time frame: upto 2 years after randomization
Bleeding Academic Research Consortium (BARC) type 3 bleeding
Time frame: upto 2 years after randomization
Bleeding Academic Research Consortium (BARC) type 5 bleeding
Time frame: upto 2 years after randomization
All-cause death, myocardial infarction, or stroke
Time frame: upto 2 years after randomization
Cardiovascular death, myocardial infarction, stent thrombosis, or stroke
Time frame: upto 2 years after randomization
All-cause death, myocardial infarction, stent thrombosis, stroke, or BARC type 3 or 5 bleeding
Time frame: upto 2 years after randomization
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for May 2027, 45 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 45 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.